Nexstim Ltd
Nexstim is a Finnish, globally operating medical technology company specializing in non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS). They develop and commercialize advanced TMS systems with highly sophisticated 3D navigation for accurate and personalized brain targeting, aiming to enable effective therapies and diagnostics for challenging brain disorders. The company emphasizes its unique, scalable technology platform, operates in a highly regulated industry with strong approvals, and focuses on growth driven by megatrends such as aging populations and technological advancements in brain health. Nexstim's strategic objectives include profitable growth, technology leadership, and expanding its product portfolio, with a committed and experienced leadership team.
Industries
Nr. of Employees
small (1-50)
Nexstim Ltd
Patents
Method and system for combining anatomical connectivity patterns and navigated brain stimulation
US-11951324-B2
View Details
Method and system for combining anatomical connectivity patterns and navigated brain stimulation
US-11951324-B2
View DetailsProducts
Navigated stimulation system for functional brain mapping
Clinical system combining MRI-derived 3D models, neuronavigation, EMG-based motor mapping and repetitive stimulation protocols for presurgical motor and language mapping.
MRI-guided repetitive stimulation therapy system
Therapeutic stimulation system that uses individual MRI-based targeting and motor-threshold calibration to deliver personalized repetitive stimulation for neuropsychiatric treatment.
Neuronavigation and planning software modules
Software tools for registration, E-field visualization, mapping result export (DICOM) and integration with surgical navigation, fiber tracking and radiosurgery planning systems.
Navigated stimulation system for functional brain mapping
Clinical system combining MRI-derived 3D models, neuronavigation, EMG-based motor mapping and repetitive stimulation protocols for presurgical motor and language mapping.
MRI-guided repetitive stimulation therapy system
Therapeutic stimulation system that uses individual MRI-based targeting and motor-threshold calibration to deliver personalized repetitive stimulation for neuropsychiatric treatment.
Neuronavigation and planning software modules
Software tools for registration, E-field visualization, mapping result export (DICOM) and integration with surgical navigation, fiber tracking and radiosurgery planning systems.
Services
Onsite and virtual demonstrations, clinician/operator training and ongoing customer support for mapping and therapy workflows.
Directory service to find clinics offering navigated mapping and therapy services.
Onsite and virtual demonstrations, clinician/operator training and ongoing customer support for mapping and therapy workflows.
Directory service to find clinics offering navigated mapping and therapy services.
Expertise Areas
- Navigated transcranial magnetic stimulation
- Presurgical functional brain mapping (motor and language)
- Repetitive TMS therapy for neuropsychiatric indications
- Integration of functional mapping into radiotherapy and surgical planning
Key Technologies
- Navigated transcranial magnetic stimulation (nTMS)
- Repetitive transcranial magnetic stimulation (rTMS)
- MRI-based 3D neuronavigation
- Electric field (E-field) simulation and visualization
News & Updates
Announcement of a system order from Hong Kong.
Order from a pediatric hospital in the United States.
Correction regarding managers' transactions.
Correction regarding managers' transactions.
FDA Clearances for Motor and Speech Mapping
Received FDA clearance for motor mapping in 2009 and speech mapping in 2012.
CE Mark and FDA Clearance for Depression and Pain Treatment
CE marked for depression and pain; FDA cleared for depression treatment.
Announcement of a system order from Hong Kong.
Order from a pediatric hospital in the United States.
Correction regarding managers' transactions.
Correction regarding managers' transactions.
FDA Clearances for Motor and Speech Mapping
Received FDA clearance for motor mapping in 2009 and speech mapping in 2012.
CE Mark and FDA Clearance for Depression and Pain Treatment
CE marked for depression and pain; FDA cleared for depression treatment.